TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30507267

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate plus electrolyte (CHO‐E) solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Electrolyte placebo
Number of subjects: 18
Study: 28159814

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 359
Study: 24296423

Group type: EXPERIMENTAL
Intervention: L. reuteri combination (2×10 Colony Forming Units)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L. reuteri combination
Number of subjects: 100
Study: 22676424

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg orally for 6 days)
Number of subjects: 11
Study: 19936616

Group type: EXPERIMENTAL
Intervention: Unilateral hypothalamic deep brain stimulation (DBS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 17509328

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (200 U)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15703774

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mental arithmetic stress test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Resting vascular resistance
Number of subjects: 58
Study: 11836455

Group type: EXPERIMENTAL
Intervention: Counseling for weight loss
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Weight/sodium reduction
Number of subjects: 585

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 585
Study: 10627793

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day flexible dose)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 8533543

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 10
Study: 1959686

Group type: EXPERIMENTAL
Intervention: Technetium-labelled-leucocyte imaging at 2-5 days post-surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Technetium-labelled-leucocyte imaging at 7-10 days post-surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinical features, leucocyte counts, and C-reactive protein measurements
Number of subjects: 20
Study: 6367380

Group type: EXPERIMENTAL
Intervention: Parenteral antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine, dihydralazine, diazoxide
Number of subjects: 0
Study: 31596866

Group type: EXPERIMENTAL
Intervention: Brief 3-week diet intervention (Diet Group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Habitual diet (Control Group)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Diet Group
Number of subjects: 101
Study: 30089078

Group type: EXPERIMENTAL
Intervention: NCRT plus surgery (group CRT)
Number of subjects: 451
Study: 26995381

Group type: EXPERIMENTAL
Intervention: Elective early aortic valve replacement (AVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management with vigilant follow-up
Number of subjects: 0
Study: 25425308

Group type: EXPERIMENTAL
Intervention: Cycle-by-cycle (CxC) ERG
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Conventional 30-Hz flicker ERG
Number of subjects: 54
Study: 22115710

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of sirolimus (220, 440, 880, 1320, or 1760 μg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of sirolimus (44, 110, 176, 264, or 352 μg)
Number of subjects: 50
Study: 21969992

Group type: EXPERIMENTAL
Intervention: Targeted maximum likelihood estimator of causal effects of multiple time point interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial estimate of the unknown factors of the G-computation formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal fluctuation function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection among different targeted maximum likelihood estimators
Number of subjects: 0
Study: 17210768

Group type: EXPERIMENTAL
Intervention: DRV/r plus ranitidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DRV/r plus omeprazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: DRV/r alone
Number of subjects: 16
Study: 17473394

Group type: EXPERIMENTAL
Intervention: Home-based cognitive training program for memory and working memory (6 weeks duration)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study: 15037403

Group type: EXPERIMENTAL
Intervention: GnRH‐a administration starting on stimulation day 6 (group 1)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: GnRH‐a administration starting when the leading follicle reached a mean diameter of 14 mm (group 2)
Number of subjects: 109
Study: 11860914

Group type: EXPERIMENTAL
Intervention: Calcium lactate tablets (800 mg of calcium daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 9229983

Group type: EXPERIMENTAL
Intervention: Aprotinin (2,000,000 IU as a bolus + 500,000 JU/h until the end of the operation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1432027

Group type: EXPERIMENTAL
Intervention: Repeated measurements of diastolic blood pressure
Number of subjects: 11299

Group type: EXPERIMENTAL
Intervention: Modeling risk of cardiovascular mortality
Number of subjects: 11299

Group type: EXPERIMENTAL
Intervention: Method of adjusting for regression dilution
Number of subjects: 11299

Group type: EXPERIMENTAL
Intervention: Sequential strategy for determining antihypertensive intervention
Number of subjects: 11299
Study: 6499663

Group type: EXPERIMENTAL
Intervention: Oral instructions alone or in combination with written information
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Medication reminder calendar
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Medication reminder package
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Combination of reminder aid with oral reinforcement
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High levels of motivation in patients
Number of subjects: 158
Study: 30876946

Group type: EXPERIMENTAL
Intervention: TDF monotherapy
Number of subjects: 192
Study: 29854085

Group type: EXPERIMENTAL
Intervention: Policosanol for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 26721327

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (HepB) booster
Number of subjects: 2
Study: 25492697

Group type: EXPERIMENTAL
Intervention: Usual care plus neural mobilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22583609

Group type: EXPERIMENTAL
Intervention: Diabetes self-management programs
Number of subjects: 75
Study: 19283599

Group type: EXPERIMENTAL
Intervention: Traditional behavioral parent training program
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enhanced behavioral parent training program - STEPP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study: 17526180

Group type: EXPERIMENTAL
Intervention: Jieyu Anshen Decoction combined with aripiprazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aripiprazole alone
Number of subjects: 100
Study: 16212807

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12529740

Group type: EXPERIMENTAL
Intervention: Aspirin plus oral anticoagulants (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aspirin alone (group A)
Number of subjects: 52
Study: 9583863

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Microemulsion cyclosporine (Neoral)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf) and Microemulsion cyclosporine (Neoral)
Number of subjects: 50
Study: 8588538

Group type: EXPERIMENTAL
Intervention: Class II below-knee compression stockings
Number of subjects: 188
Study: 2799345

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate
Number of subjects: 22
Study: 1090418

Group type: EXPERIMENTAL
Intervention: Indapamide (5 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Chlorothiazide (500 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30973182

Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Coffee with milk
Number of subjects: 54

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 54
Study: 27685010

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistive exercise only (RE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 24
Study: 25698298

Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT + Treatment as Usual (TAU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT + TAU
Number of subjects: 94
Study: 24238308

Group type: EXPERIMENTAL
Intervention: Mesna injection
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 101
Study: 22852055

Group type: EXPERIMENTAL
Intervention: Natural orange juice enriched with 11.25 g of levan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Natural orange juice without levan
Number of subjects: 48
Study: 19254123

Group type: COMPARATOR
Intervention: CPT plus ADM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPT plus ADM and PRP
Number of subjects: 18
Study: 17448057

Group type: EXPERIMENTAL
Intervention: Manual displacement of the uterus (group MD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15 degrees left lateral table tilt (group LT)
Number of subjects: 90
Study: 14736583

Group type: EXPERIMENTAL
Intervention: e-diaries administered via home visits (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: p-diaries handed out during clinic visits for return by mail (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: e-diaries
Number of subjects: 60
Study: 12610173

Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol
Number of subjects: 177

Group type: COMPARATOR
Intervention: LALA‐94 protocol
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol (B-lineage ALL)
Number of subjects: 177

Group type: COMPARATOR
Intervention: LALA‐94 protocol (B-lineage ALL)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol (T-lineage ALL)
Number of subjects: 177
Study: 10577813

Group type: EXPERIMENTAL
Intervention: Surgical treatment with ventilation tubes
Number of subjects: 0
Study: 8597505

Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-Fluorouracil and cisplatin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 120
Study: 1936647

Group type: EXPERIMENTAL
Intervention: Occlusin restorations in butt-joint preparations
Number of subjects: 94

Group type: COMPARATOR
Intervention: Occlusin restorations in bevel-edged preparations
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Large-sized Class II restorations in molar teeth
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Class I restorations
Number of subjects: 94
Study: 7062298

Group type: EXPERIMENTAL
Intervention: Low GHQ scores
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: High GHQ scores
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Medium GHQ scores
Number of subjects: 320
Study: 31270846

Group type: EXPERIMENTAL
Intervention: NMES (neuromuscular external electrical stimulation device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator device (iTouch sure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both NMES and comparator device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 0
Study: 27500896

Group type: EXPERIMENTAL
Intervention: Serial glycolic acid (GA) peel every 3 weeks with twice daily 20% azelaic acid (AA) cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20% azelaic acid (AA) cream
Number of subjects: 60
Study: 26763917

Group type: EXPERIMENTAL
Intervention: 300 mg triflusal twice a day
Number of subjects: 1080

Group type: COMPARATOR
Intervention: 75 mg clopidogrel once daily
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1080
Study: 24240777

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment aimed at lowering systolic blood pressure by 10% to 25% within the first 24 hours, achieving blood pressure less than 140/90 mm Hg within 7 days, and maintaining this level during hospitalization.
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control group (discontinued all antihypertensive medications during hospitalization).
Number of subjects: 4071

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment group.
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 4071
Study: 22093005

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) juice powder concentrates
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable/Berry (FVB) juice powder concentrates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18562427

Group type: EXPERIMENTAL
Intervention: alprazolam 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: zolpidem 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 17155987

Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15619403

Group type: EXPERIMENTAL
Intervention: Nonpolymeric paclitaxel-coated stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 12477009

Group type: EXPERIMENTAL
Intervention: Experimental group informed of the blue team's aggressive reputation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not informed of the blue team's aggressive reputation
Number of subjects: 38
Study: 9163287

Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease (EUCTD, rheumatoid arthritis, lupus, polymyositis)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease (EUCTD, rheumatoid arthritis, lupus)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (blood donors and patients with known vasculitis)
Number of subjects: 453
Study: 8424580

Group type: EXPERIMENTAL
Intervention: Intermittent suction and pressure treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 34
Study: 3315536

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg once a day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 31751317

Group type: EXPERIMENTAL
Intervention: FMT capsules from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 20
Study: 27473187

Group type: EXPERIMENTAL
Intervention: CYP2R1 genetic polymorphisms (rs1562902 and rs10741657 SNPs)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: CYP2R1 genetic polymorphisms (rs10766197 and rs12794714 SNPs)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (600 IU daily or 3750 IU daily)
Number of subjects: 218
Study: 29509347

Group type: EXPERIMENTAL
Intervention: Quad-helix appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 40
Study: 24576844

Group type: EXPERIMENTAL
Intervention: Fish oil-based parenteral lipid preparation (FOLP) at 1.5 g/kg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soy-based parenteral lipid preparation (SLP) at 1.5 g/kg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fish oil-based parenteral lipid preparation (FOLP)
Number of subjects: 16
Study: 22682229

Group type: EXPERIMENTAL
Intervention: Combined universal and targeted program (Toddlers Without Tears group parenting program followed by Family Check‐Up one‐on‐one program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted Family Check‐Up program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19448211

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 64) via ACD (end‐tidal 0.5‐1 vol%)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Propofol (n = 61)
Number of subjects: 125
Study: 17617556

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NFSC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AUC A
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AUC B
Number of subjects: 25
Study: 15102335

Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 15
Study: 11248812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 9568728

Group type: EXPERIMENTAL
Intervention: IFN-alpha (150 IU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sucralfate (250 mg)
Number of subjects: 60
Study: 8142151

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone (arm I: 26 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CT combined with IFN‐gamma (arm II: 27 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CT combined with both IFN‐gamma and IFN‐alpha (arm III: 27 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 80
Study: 3060424

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet once a month
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet once a month (after relapse)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet twice a month
Number of subjects: 85
Study: 1360087

Group type: EXPERIMENTAL
Intervention: Early administration of Exosurf (synthetic surfactant)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: Delayed selective administration of Exosurf (synthetic surfactant)
Number of subjects: 2690

Group type: EXPERIMENTAL
Intervention: Up-to-four doses of surfactant (if signs of RDS persisted or recurred)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: Two doses of surfactant 12 hours apart
Number of subjects: 2690
Study: 692138

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (chemotherapy, radiotherapy, immunotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Curative resection
Number of subjects: 0
Study: 31818089

Group type: EXPERIMENTAL
Intervention: Orogastric tube guide (GTG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional 'blind' technique (CONV)
Number of subjects: 151
Study: 29923748

Group type: EXPERIMENTAL
Intervention: Values intervention (n = 18)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (n = 14)
Number of subjects: 32
Study: 28857772

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 24814382

Group type: EXPERIMENTAL
Intervention: Prudent low-fat breakfast (PB) based on Nordic foods provided ad libitum
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual breakfast (Control)
Number of subjects: 79
Study: 23506397

Group type: EXPERIMENTAL
Intervention: MAPS intervention (HE + up to 18 MAPS counseling calls over 18 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 400
Study: 21356006

Group type: EXPERIMENTAL
Intervention: 2% green tea rinse for 5 minutes
Number of subjects: 25
Study: 19220164

Group type: EXPERIMENTAL
Intervention: New formulation of azelastine nasal spray
Number of subjects: 862

Group type: COMPARATOR
Intervention: Original formulation of azelastine nasal spray
Number of subjects: 862
Study: 16618912

Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency tonsil reduction and adenoidectomy (TCRF&A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional tonsillectomy and adenoidectomy (T&A)
Number of subjects: 23
Study: 15531313

Group type: EXPERIMENTAL
Intervention: Topical Anesthesia (TA)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Retrobulbar Anesthesia (RA)
Number of subjects: 306
Study: 11712341

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no morphine)
Number of subjects: 50
Study: 9152099

Group type: EXPERIMENTAL
Intervention: Continuous low dose (2.5‐10 mg every 2 weeks)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Targeted, early intervention (fluphenazine only when symptomatic)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Continuous moderate dose (standard) (12.5‐50 mg every 2 weeks)
Number of subjects: 313
Study: 8424849

Group type: EXPERIMENTAL
Intervention: 0.5 mg SDZ ENA 713
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg SDZ ENA 713
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.3 mg SDZ ENA 713
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg SDZ ENA 713
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3306291

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day, per os)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 124
Study: 31628001

Group type: EXPERIMENTAL
Intervention: Unplanned landings
Number of subjects: 20
Study: 30777015

Group type: COMPARATOR
Intervention: Conventional group (algorithm based on conventional coagulation assays: platelet count, aPTT, PT, fibrinogen)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Point-of-care (PoC) group (monitoring using activated rotational thromboelastometry (ROTEM®) combined with multiple aggregometry (Multiplate®))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both groups (Conventional and PoC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PoC group only
Number of subjects: 26
Study: 27339124

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine PAI
Number of subjects: 119

Group type: COMPARATOR
Intervention: Morphine spinal anesthesia
Number of subjects: 119

Group type: COMPARATOR
Intervention: Ropivacaine PAI
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 119